Palmitoylethanolamide (PEA) for Parkinson's Disease
Also known as: PEA, Normast, Levagen
Neuroinflammation mediated by activated microglia and mast cells contributes to dopaminergic neuron loss in Parkinson's.
Mechanism of Action
PEA dampens microglial-driven neuroinflammation in the nigrostriatal pathway, stabilizes mast cells in the brain, and activates PPARα-dependent anti-inflammatory gene expression. It may also modulate α-synuclein-induced inflammatory responses.
General mechanism: Endocannabinoid-like lipid. PPARα agonist, mast cell stabilizer, NF-κB inhibitor, neuroinflammation modulator.
Current Evidence
Preclinical PD models show dopaminergic neuroprotection. PEA is used clinically for PD-related pain in Europe. Disease-modification studies are early.
Clinical Status: Preclinical for PD neuroprotection. Clinical use for PD pain in Europe.
Safety Profile
Excellent safety. No psychoactive effects. No significant drug interactions. Micronized form improves absorption.
Key Research Questions
- Can PEA address both motor and non-motor symptoms in PD?
- Does PEA modulate α-synuclein-driven neuroinflammation?